Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Gabriel, Hortobagyi"'
Autor:
Nagi S. El Saghir, Benjamin O. Anderson, Julie Gralow, Gilberto Lopes, Lawrence N. Shulman, Hiba A. Moukadem, Peter Paul Yu, Gabriel Hortobagyi
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 185-189 (2020)
PURPOSE Brain drain is the migration of educated and skilled individuals from a less developed region or country to a more economically established one. The Trump administration proposed a merit-based immigration plan. This article addresses its pote
Externí odkaz:
https://doaj.org/article/8326055046b44ee68ce285d34cb4434f
Autor:
Nancy U. Lin, Rashmi K. Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L. Bedard, Virginia Borges, David Cameron, Lisa A. Carey, A. Jo Chien, Giuseppe Curigliano, Michael P. DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara A. Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
Publikováno v:
Scientia
U. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G, A. Hurvitz, S, Krop, I, Loi, S, Loibl, S, Mueller, V, Oliveira, M, Paplomata, E, Pegram, M, Slamon, D, Zelnak, A, Ramos, J, Feng, W & Winer, E 2022, ' Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2022.5610
U. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G, A. Hurvitz, S, Krop, I, Loi, S, Loibl, S, Mueller, V, Oliveira, M, Paplomata, E, Pegram, M, Slamon, D, Zelnak, A, Ramos, J, Feng, W & Winer, E 2022, ' Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial ', JAMA Oncology . https://doi.org/10.1001/jamaoncol.2022.5610
ImportanceIt is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f800399cc04de7baef3960b16afc0f9b
https://hdl.handle.net/11351/9527
https://hdl.handle.net/11351/9527
Autor:
Kevin M Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori A Goldstein, Stephen KL Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H Arce-Salinas, Etienne GC Brain, Eun Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vasquez, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steven Shak, Priyanka Sharma, Danika Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel Hortobagyi
Publikováno v:
Cancer Research. 82:GS2-07
Background: We previouslyreported that invasive disease-free survival (IDFS), the primary outcome, and distantdisease-free survival (DDFS), a secondary outcome, differed by menopausalstatus in a pre-specified analysis. Here,we report updates on IDFS
Autor:
Young Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, Benedito Carneiro, Nisha Mohindra, Francis Joseph Giles, Praveen Ramakrishnan-Geethakumari, Joohyuk Sohn, Shuying Liu, Huiqin Chen, Naoto Ueno, Gabriel Hortobagyi, Ana Maria Gonzalez-Angulo
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0152585 (2016)
EGFR and cMET cross-talk is involved in breast cancer (BC) progression and resistance to different targeted therapies, however little is known about the co-expression patterns of EGFR and cMET or its prognostic significance in BC. Protein levels of E
Externí odkaz:
https://doaj.org/article/b1f44ede706548a1b30f6e2774735933
Publikováno v:
Breast Cancer Radiation Therapy ISBN: 9783030911690
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52f2072c16c19fe49c877703a20c6913
https://doi.org/10.1007/978-3-030-91170-6_2
https://doi.org/10.1007/978-3-030-91170-6_2
Autor:
Fabio, Conforti, Laura, Pala, Vincenzo, Bagnardi, Tommaso, De Pas, Marco, Colleoni, Marc, Buyse, Gabriel, Hortobagyi, Luca, Gianni, Eric, Winer, Sibylle, Loibl, Javier, Cortes, Martine, Piccart, Antonio C, Wolff, Giuseppe, Viale, Richard D, Gelber
Publikováno v:
JAMA Oncology. 8:1668
ImportanceThe pathologic complete response (pCR) is supported by regulatory agencies as a surrogate end point for long-term patients’ clinical outcomes in the accelerated approval process of new drugs tested in neoadjuvant randomized clinical trial
Autor:
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe Bedard, Virginia Borges, David Cameron, Lisa Carey, A Jo Chien, Giuseppe Curigliano, Michael DiGiovanna, Karen Gelmon, Gabriel Hortobagyi, Sara Hurvitz, Ian Krop, Sherene Loi, Sibylle Loibl, Volkmar Mueller, Mafalda Oliveira, Elisavet Paplomata, Mark Pegram, Dennis Slamon, Amelia Zelnak, Jorge Ramos, Wentao Feng, Eric Winer
Publikováno v:
Cancer Research. 82:PD4-04
Background: Tucatinib is an oral tyrosine kinase inhibitor highly specific for HER2 that is approved for use in combination with trastuzumab and capecitabine in adults with advanced or metastatic HER2+ breast cancer, including patients with brain met
Publikováno v:
Human Gene Therapy. 7:401-416
Publikováno v:
The Breast Journal. 1:96-101
Tumor response to preoperative chemotherapy varies from complete to partial to none. To evaluate pathologic predictors of tumor response to preoperative chemotherapy, we reviewed 287 cases of locally advanced breast carcinoma treated with chemotherap
Autor:
Patricia K, Corey-Lisle, Ronald, Peck, Pralay, Mukhopadhyay, Lucinda, Orsini, Shima, Safikhani, Jill A, Bell, Gabriel, Hortobagyi, Henri, Roche, Pierfranco, Conte, Dennis A, Revicki
Combination therapy with ixabepilone and capecitabine (cape) is approved for use in patients with locally advanced/metastatic breast cancer that is resistant to treatment with anthracyclines or taxanes. The current study evaluated the trade-off betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::efbc6c171705b7036dbca015ab92a571
https://hdl.handle.net/11380/738546
https://hdl.handle.net/11380/738546